Gene fusion targeted therapy
View Patent ↗The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.
1. A method of inhibiting the expression of an ERG gene in a cell, comprising contacting said cell with an siRNA against ERG, wherein said siRNA has the sequence of one of SEQ ID NOS: 30-41.
2. The method of claim 1 , wherein said cell is a cancer cell.
3. The method of claim 2 , wherein said cancer cell is a prostate cancer cell.
4. The method of claim 1 , wherein said cell is in vivo.
5. The method of claim 4 , wherein said cell is in an animal.
6. The method of claim 5 , wherein said animal is a human.
7. The method of claim 1 , wherein said cell is ex vivo.
8. The method of claim 1 , wherein said ERG gene is fused to TMPRSS2.
9. A kit, comprising a pharmaceutical composition that inhibits the expression of an ERG gene in a cell, wherein said composition comprises an siRNA against ERG, and wherein said siRNA has the sequence of one of SEQ ID NOS: 30-41.